- Current report filing (8-K)
January 14 2009 - 1:48PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
January 14, 2009
BRUKER CORPORATION
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-30833
|
|
04-3110160
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
|
|
|
|
|
40
Manning Road
Billerica, MA 01821
(Address of
principal executive offices)(Zip Code)
|
|
Registrants
telephone number, including area code:
(978) 663-3660
|
Check
the appropriate box if the Form 8-K filing is intended to simultaneously
satisfy the reporting obligation of the registrant under any of the following
provisions:
o
|
Written
communications pursuant to Rule 425 under the Securities Act
|
o
|
Soliciting
material pursuant to Rule 14a-12 of the Exchange Act
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) Exchange Act
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) Exchange Act
|
Item
2.02
Results
of Operations and Financial Condition.
On January 14, 2009,
Bruker Corporation (the Company) will participate in the 27
th
Annual J.P.
Morgan Healthcare Conference in San Francisco, California. The presentation materials, a copy of which
are attached hereto as Exhibit 99.1, on slide 12 contain previously non-public
information relating to (i) preliminary, unaudited revenue estimates, (ii)
further net debt reduction, and (iii) qualitative comments on order bookings in
the recently completed fourth quarter of fiscal 2008.
The information in this Current Report on Form 8-K,
including
exhibits
attached hereto
and the information under Item 7.01 below,
is being furnished and shall not
be deemed filed for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section and shall not be deemed incorporated by
reference into any filing by the Company under the Securities Act of 1933, as
amended, or the Exchange Act, unless specifically identified therein as being
incorporated by reference therein.
Item
7.01
Regulation
FD Disclosure.
The information set forth in Item 2.02 is incorporated
herein in its entirety. The slides that will accompany Company managements
presentation at the above-referenced conference, attached to this Current
Report on Form 8-K as Exhibit 99.1, are also posted on the
Companys investor relations website at http://www.bruker.com.
Item 9.01
Financial Statements and
Exhibits.
(d) Exhibits.
Exhibit No. 99.1
|
|
January 14, 2009
Presentation at the 27
th
Annual J.P. Morgan Healthcare Conference
.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
BRUKER CORPORATION
|
|
(Registrant)
|
|
|
Date: January 14 ,
2009
|
By:
|
|
|
|
/s/
Frank
H. Laukien
|
|
|
Frank H. Laukien,
Ph.D.
|
|
|
Chief
Executive Officer and President
|
3
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024